Annual FCF
-$257.90 M
-$108.00 M-72.05%
31 December 2023
Summary:
Emergent BioSolutions annual free cash flow is currently -$257.90 million, with the most recent change of -$108.00 million (-72.05%) on 31 December 2023. During the last 3 years, it has fallen by -$652.90 million (-165.29%). EBS annual FCF is now -165.29% below its all-time high of $395.00 million, reached on 31 December 2020.EBS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$147.90 M
+$105.00 M+244.76%
30 September 2024
Summary:
Emergent BioSolutions quarterly free cash flow is currently $147.90 million, with the most recent change of +$105.00 million (+244.76%) on 30 September 2024. Over the past year, it has increased by +$100.50 million (+212.03%). EBS quarterly FCF is now -47.61% below its all-time high of $282.30 million, reached on 31 December 2021.EBS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$138.10 M
+$100.50 M+267.29%
30 September 2024
Summary:
Emergent BioSolutions TTM free cash flow is currently $138.10 million, with the most recent change of +$100.50 million (+267.29%) on 30 September 2024. Over the past year, it has increased by +$347.50 million (+165.95%). EBS TTM FCF is now -65.04% below its all-time high of $395.00 million, reached on 31 December 2020.EBS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -72.0% | +212.0% | +165.9% |
| 3 y3 years | -165.3% | +484.2% | +503.1% |
| 5 y5 years | -751.2% | +903.8% | +180.5% |
EBS Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -165.3% | at low | -47.6% | +174.3% | at high | +138.5% |
| 5 y | 5 years | -165.3% | at low | -47.6% | +174.3% | -65.0% | +138.5% |
| alltime | all time | -165.3% | at low | -47.6% | +174.3% | -65.0% | +138.5% |
Emergent BioSolutions Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $147.90 M(+244.8%) | $138.10 M(+267.3%) |
| June 2024 | - | $42.90 M(-158.4%) | $37.60 M(-128.4%) |
| Mar 2024 | - | -$73.40 M(-454.6%) | -$132.20 M(-48.7%) |
| Dec 2023 | -$257.90 M(+72.0%) | $20.70 M(-56.3%) | -$257.90 M(+23.2%) |
| Sept 2023 | - | $47.40 M(-137.4%) | -$209.40 M(-41.6%) |
| June 2023 | - | -$126.90 M(-36.3%) | -$358.70 M(+28.3%) |
| Mar 2023 | - | -$199.10 M(-387.7%) | -$279.50 M(+86.5%) |
| Dec 2022 | -$149.90 M(-256.0%) | $69.20 M(-167.9%) | -$149.90 M(-337.2%) |
| Sept 2022 | - | -$101.90 M(+113.6%) | $63.20 M(-50.1%) |
| June 2022 | - | -$47.70 M(-31.4%) | $126.60 M(+63.1%) |
| Mar 2022 | - | -$69.50 M(-124.6%) | $77.60 M(-19.3%) |
| Dec 2021 | $96.10 M(-75.7%) | $282.30 M(-833.2%) | $96.10 M(+319.7%) |
| Sept 2021 | - | -$38.50 M(-60.2%) | $22.90 M(-81.1%) |
| June 2021 | - | -$96.70 M(+89.6%) | $120.90 M(-61.1%) |
| Mar 2021 | - | -$51.00 M(-124.4%) | $310.40 M(-21.4%) |
| Dec 2020 | $395.00 M(+290.7%) | $209.10 M(+251.4%) | $395.00 M(+45.3%) |
| Sept 2020 | - | $59.50 M(-35.9%) | $271.90 M(+40.2%) |
| June 2020 | - | $92.80 M(+176.2%) | $194.00 M(+278.2%) |
| Mar 2020 | - | $33.60 M(-60.9%) | $51.30 M(-49.3%) |
| Dec 2019 | $101.10 M(-433.7%) | $86.00 M(-567.4%) | $101.10 M(-159.0%) |
| Sept 2019 | - | -$18.40 M(-63.1%) | -$171.50 M(+3198.1%) |
| June 2019 | - | -$49.90 M(-159.8%) | -$5.20 M(-107.9%) |
| Mar 2019 | - | $83.40 M(-144.7%) | $65.70 M(-316.8%) |
| Dec 2018 | -$30.30 M(-119.8%) | -$186.60 M(-226.2%) | -$30.30 M(-113.7%) |
| Sept 2018 | - | $147.90 M(+604.3%) | $221.37 M(+131.5%) |
| June 2018 | - | $21.00 M(-266.7%) | $95.63 M(-19.9%) |
| Mar 2018 | - | -$12.60 M(-119.4%) | $119.33 M(-22.2%) |
| Dec 2017 | $153.30 M(-809.7%) | $65.07 M(+193.6%) | $153.30 M(+175.6%) |
| Sept 2017 | - | $22.16 M(-50.4%) | $55.63 M(+27.8%) |
| June 2017 | - | $44.70 M(+109.2%) | $43.54 M(-280.0%) |
| Mar 2017 | - | $21.37 M(-165.5%) | -$24.19 M(+12.0%) |
| Dec 2016 | -$21.60 M(+841.2%) | -$32.61 M(-423.5%) | -$21.60 M(-2361.8%) |
| Sept 2016 | - | $10.08 M(-143.8%) | $955.00 K(-98.8%) |
| June 2016 | - | -$23.03 M(-196.1%) | $81.69 M(-15.5%) |
| Mar 2016 | - | $23.96 M(-338.3%) | $96.62 M(-4309.9%) |
| Dec 2015 | -$2.29 M | -$10.05 M(-111.1%) | -$2.29 M(-105.3%) |
| Sept 2015 | - | $90.81 M(-1221.7%) | $43.53 M(+64.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | -$8.10 M(-89.2%) | $26.42 M(-34.8%) |
| Mar 2015 | - | -$74.95 M(-309.6%) | $40.52 M(-50.4%) |
| Dec 2014 | $81.64 M(+48.6%) | $35.77 M(-51.5%) | $81.64 M(+74.0%) |
| Sept 2014 | - | $73.70 M(+1126.5%) | $46.92 M(+259.7%) |
| June 2014 | - | $6.01 M(-117.8%) | $13.04 M(-61.0%) |
| Mar 2014 | - | -$33.84 M(-3353.4%) | $33.42 M(-39.2%) |
| Dec 2013 | $54.95 M(-486.9%) | $1.04 M(-97.4%) | $54.95 M(+2666.7%) |
| Sept 2013 | - | $39.83 M(+51.0%) | $1.99 M(-243.9%) |
| June 2013 | - | $26.38 M(-314.4%) | -$1.38 M(-92.3%) |
| Mar 2013 | - | -$12.30 M(-76.3%) | -$18.02 M(+26.9%) |
| Dec 2012 | -$14.20 M(-66.1%) | -$51.92 M(-242.4%) | -$14.20 M(-125.9%) |
| Sept 2012 | - | $36.46 M(+274.1%) | $54.78 M(+874.9%) |
| June 2012 | - | $9.75 M(-214.8%) | $5.62 M(-129.3%) |
| Mar 2012 | - | -$8.49 M(-149.8%) | -$19.18 M(-54.2%) |
| Dec 2011 | -$41.84 M(-155.1%) | $17.06 M(-234.4%) | -$41.84 M(-5.6%) |
| Sept 2011 | - | -$12.70 M(-15.6%) | -$44.30 M(-358.2%) |
| June 2011 | - | -$15.05 M(-51.7%) | $17.16 M(-47.0%) |
| Mar 2011 | - | -$31.16 M(-313.4%) | $32.39 M(-57.3%) |
| Dec 2010 | $75.92 M(-2834.9%) | $14.60 M(-70.1%) | $75.92 M(+297.0%) |
| Sept 2010 | - | $48.76 M(>+9900.0%) | $19.13 M(-1308.9%) |
| June 2010 | - | $191.00 K(-98.5%) | -$1.58 M(-104.0%) |
| Mar 2010 | - | $12.37 M(-129.3%) | $39.80 M(-1533.6%) |
| Dec 2009 | -$2.78 M(-79.4%) | -$42.20 M(-250.4%) | -$2.78 M(-112.0%) |
| Sept 2009 | - | $28.05 M(-32.5%) | $23.13 M(+108.4%) |
| June 2009 | - | $41.57 M(-237.6%) | $11.10 M(-135.0%) |
| Mar 2009 | - | -$30.20 M(+85.4%) | -$31.74 M(+135.2%) |
| Dec 2008 | -$13.50 M(-217.6%) | -$16.29 M(-201.7%) | -$13.50 M(-118.2%) |
| Sept 2008 | - | $16.02 M(-1360.6%) | $74.16 M(+89.3%) |
| June 2008 | - | -$1.27 M(-89.4%) | $39.18 M(+3103.4%) |
| Mar 2008 | - | -$11.96 M(-116.8%) | $1.22 M(-89.3%) |
| Dec 2007 | $11.48 M(-125.3%) | $71.37 M(-476.4%) | $11.48 M(-119.2%) |
| Sept 2007 | - | -$18.96 M(-51.7%) | -$59.89 M(+46.3%) |
| June 2007 | - | -$39.23 M(+2202.0%) | -$40.93 M(+2302.0%) |
| Mar 2007 | - | -$1.70 M | -$1.70 M |
| Dec 2006 | -$45.29 M(-226.8%) | - | - |
| Dec 2005 | $35.72 M(-553.5%) | - | - |
| Dec 2004 | -$7.88 M | - | - |
FAQ
- What is Emergent BioSolutions annual free cash flow?
- What is the all time high annual FCF for Emergent BioSolutions?
- What is Emergent BioSolutions annual FCF year-on-year change?
- What is Emergent BioSolutions quarterly free cash flow?
- What is the all time high quarterly FCF for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly FCF year-on-year change?
- What is Emergent BioSolutions TTM free cash flow?
- What is the all time high TTM FCF for Emergent BioSolutions?
- What is Emergent BioSolutions TTM FCF year-on-year change?
What is Emergent BioSolutions annual free cash flow?
The current annual FCF of EBS is -$257.90 M
What is the all time high annual FCF for Emergent BioSolutions?
Emergent BioSolutions all-time high annual free cash flow is $395.00 M
What is Emergent BioSolutions annual FCF year-on-year change?
Over the past year, EBS annual free cash flow has changed by -$108.00 M (-72.05%)
What is Emergent BioSolutions quarterly free cash flow?
The current quarterly FCF of EBS is $147.90 M
What is the all time high quarterly FCF for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly free cash flow is $282.30 M
What is Emergent BioSolutions quarterly FCF year-on-year change?
Over the past year, EBS quarterly free cash flow has changed by +$100.50 M (+212.03%)
What is Emergent BioSolutions TTM free cash flow?
The current TTM FCF of EBS is $138.10 M
What is the all time high TTM FCF for Emergent BioSolutions?
Emergent BioSolutions all-time high TTM free cash flow is $395.00 M
What is Emergent BioSolutions TTM FCF year-on-year change?
Over the past year, EBS TTM free cash flow has changed by +$347.50 M (+165.95%)